for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Concert Pharmaceuticals Inc

CNCE.OQ

Latest Trade

6.15USD

Change

0.06(+0.99%)

Volume

46,275

Today's Range

6.00

 - 

6.22

52 Week Range

5.36

 - 

17.80

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.09
Open
6.12
Volume
46,275
3M AVG Volume
4.84
Today's High
6.22
Today's Low
6.00
52 Week High
17.80
52 Week Low
5.36
Shares Out (MIL)
23.80
Market Cap (MIL)
144.94
Forward P/E
-1.80
Dividend (Yield %)
--

Latest Developments

More

Concert Pharma Reports Positive CTP-543 Results From Phase 2 Alopecia Areata Trial

Concert Pharmaceuticals Q2 Loss Per Share $0.78

Concert Pharma Reports Positive Results From Early-Stage Studies Testing Its Experimental Schizophrenia Treatment

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Concert Pharmaceuticals Inc

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.

Industry

Biotechnology & Drugs

Contact Info

65 Hayden Ave Ste 3000N

+1.781.8600045

https://www.concertpharma.com/

Executive Leadership

Richard H. Aldrich

Independent Chairman of the Board, Co-Founder

Roger D. Tung

President, Chief Executive Officer, Co-Founder, Director

Marc Becker

Chief Financial Officer

Nancy Stuart

Chief Operating Officer

James V. Cassella

Chief Development Officer

Key Stats

2.00 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.1K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.280

2017

4.060

2018

-2.400

2019(E)

-3.387
Price To Earnings (TTM)
--
Price To Sales (TTM)
134.45
Price To Book (MRQ)
1.07
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-42.15
Return on Equity (TTM)
-40.68

Latest News

Latest News

BRIEF-Concert Pharmaceuticals Reports Q1 Loss Per Share $0.19

* CONCERT PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Concert Pharmaceuticals Completes Enrollment In Phase 2A Trial Of CTP-543 In Alopecia Areata

* CONCERT PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE 2A TRIAL OF CTP-543 IN ALOPECIA AREATA

BRIEF-Concert Pharmaceuticals Inc Files For Mixed Shelf Offering Of Up To $250.0 Million - SEC Filing

* CONCERT PHARMACEUTICALS INC FILES FOR MIXED SHELF OFFERING OF UP TO $250.0 MILLION - SEC FILING Source text (http://bit.ly/2t6Qumw) Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Concert Pharmaceuticals Reports Qtrly Loss Per Share $0.26

* CONCERT PHARMACEUTICALS REPORTS YEAR ENDED 2017 FINANCIAL RESULTS

BRIEF-Concert Pharma Says Intends To Complete Evaluation And Advance CTP-692 Into Clinical Development By 2018 End

* CONCERT PHARMACEUTICALS INC SAYS INTENDS TO COMPLETE PRECLINICAL EVALUATION AND ADVANCE CTP-692 INTO CLINICAL DEVELOPMENT BY YEAR-END 2018 Source text for Eikon: Further company coverage:

BRIEF-Concert Pharmaceuticals Initiates Enrollment In Second Cohort Of CTP-543 Trial

* CONCERT PHARMACEUTICALS ANNOUNCES INITIATION OF ENROLLMENT IN SECOND COHORT OF CTP-543 PHASE 2A TRIAL FOR ALOPECIA AREATA

BRIEF-Concert Pharma Says FDA Granted Fast Track Designation To CTP-543

* FDA GRANTS FAST TRACK DESIGNATION TO CONCERT PHARMACEUTICALS’ CTP-543 FOR THE TREATMENT OF ALOPECIA AREATA

BRIEF-Concert Pharmaceuticals Announces Patent Trial And Appeal Board Did Not Institute PGR Proceeding

* CONCERT PHARMACEUTICALS ANNOUNCES PATENT TRIAL AND APPEAL BOARD DID NOT INSTITUTE PGR PROCEEDING Source text for Eikon: Further company coverage:

BRIEF-Concert Pharmaceuticals Announces Appointment Of Marc Becker As CFO

* CONCERT PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF MARC BECKER AS CHIEF FINANCIAL OFFICER

BRIEF-Concert Pharmaceuticals reports Q3 earnings per share $5.61

* Concert Pharmaceuticals reports third quarter 2017 financial results and provides company update

BRIEF-Concert Pharmaceuticals announces completion of enrollment in First Cohort of CTP-543 phase 2a trial

* Concert Pharmaceuticals Inc announces completion of enrollment in First Cohort of CTP-543 phase 2a trial

BRIEF-Concert Pharma pays total of $30.8 mln to Hercules Capital

* Concert Pharmaceuticals- on Sept 7, paid total of $30.8 million to hercules capital outstanding under loan and security agreement with Hercules dated June 8

BRIEF-Concert Pharmaceuticals reports Q2 loss per share $0.58

* Concert Pharmaceuticals reports second quarter 2017 financial results and provides company update

BRIEF-Vertex and Concert Pharmaceuticals complete asset purchase agreement

* Vertex and Concert Pharmaceuticals complete asset purchase agreement for CTP-656 Source text for Eikon: Further company coverage:

BRIEF-Concert Pharmaceuticals terminates Hart-Scott-Rodino act waiting period for CTP-656 asset purchase agreement

* Concert Pharmaceuticals announces termination of the Hart-Scott-Rodino act waiting period for CTP-656 asset purchase agreement with Vertex

FDA lifts hold on Concert Pharma's study testing hair loss drug

Concert Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) lifted a clinical hold on a trial testing its therapy for alopecia areata, a type of hair loss.

BRIEF-Concert Pharma says FDA lifts clinical hold on its clinical trial with CTP-543

* Fda lifts clinical hold on concert pharmaceuticals clinical trial with ctp-543

FDA lifts hold on Concert Pharma's hair loss drug

Concert Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration lifted the clinical hold on a mid-stage study testing its drug to treat alopecia areata, a type of hair loss.

BRIEF-Concert pharmaceuticals announces $30 million venture debt financing from hercules capital

* Concert pharmaceuticals announces $30 million venture debt financing from Hercules Capital

BRIEF-Concert Pharmaceuticals announces departure of CFO, Ryan Daws

* Concert Pharmaceuticals announces departure of chief financial officer, Ryan Daws

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up